GCM
CLB icon

Graham Capital Management’s Core Laboratories CLB Stock Holding History

Graham Capital Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,615
Closed -$423K – 1041
2023
Q3 		$423K Sell
17,615
-9,178
-34% -$225K 0.01% 612
2023
Q2 		$623K Sell
26,793
-12,476
-32% -$282K 0.02% 496
2023
Q1 		$866K Buy
39,269
+1,078
+3% +$25.2K 0.03% 567
2022
Q4 		$774K Sell
38,191
-7,777
-17% -$151K 0.02% 631
2022
Q3 		$619K Sell
45,968
-70,604
-61% -$1.19M 0.02% 673
2022
Q2 		$2.31M Buy
116,572
+81,995
+237% +$2.18M 0.09% 167
2022
Q1 		$1.09M Buy
+34,577
New +$969K 0.04% 279
2017
Q3 		– Sell
-6,000
Closed -$608K – 60
2017
Q2 		$608K Buy
+6,000
New +$647K 0.02% 76
2013
Q4 		– Sell
-13,000
Closed -$2.2M – 125
2013
Q3 		$2.2M Buy
13,000
+2,000
+18% +$310K 0.14% 85
2013
Q2 		$1.67M Buy
+11,000
New +$1.56M 0.11% 64

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Graham Capital Management's CLB Position: Q4 2023 in Review

Graham Capital Management sold out of Core Laboratories (CLB) in Q4 2023, closing a stake of 17,615 shares — an estimated $423K sold.

Graham Capital Management first reported a position in CLB in Q2 2013 and held it in 10 quarters. The position peaked at $2.31M in Q2 2022. 186 funds tracked by Wall St. Rank hold CLB as of Q4 2023.

  • Graham Capital Management reported no remaining Core Laboratories position as of Q4 2023 after selling out during the quarter.
  • Graham Capital Management sold 17,615 Core Laboratories shares in Q4 2023, an estimated $423K.
  • Graham Capital Management first reported a position in Core Laboratories in Q2 2013 and held it in 10 quarters.
  • Graham Capital Management's Core Laboratories position peaked at $2.31M in Q2 2022.
  • 186 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2023.

Based on Graham Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.